1 ied the function of liver PPAR gamma in both
lipoatrophic A-ZIP/F-1 (AZIP) and wild type mice.
2 the beta3 effects studied were absent in the
lipoatrophic A-ZIP/F-1 mice, including the effects on no
3 In
lipoatrophic A-ZIP/F-1 mice, transplantation of normal a
4 In
lipoatrophic A-ZIP/F1 'fatless' mice, which are genetica
5 group, raising the possibility of a specific
lipoatrophic activity for leptin.
6 These alterations result in a cellular
lipoatrophic condition that compromises uterine tissue i
7 suggests a mouse model for the human disease
lipoatrophic diabetes (Seip-Berardinelli syndrome), indi
8 are rescued from neonatal death, but develop
lipoatrophic diabetes and die prematurely.
9 NASH associated with
lipoatrophic diabetes can recur after liver transplantat
10 Lipoatrophic diabetes is an insulin resistance syndrome
11 le of PPARalpha agonists in the treatment of
lipoatrophic diabetes is warranted.
12 article describes the first reported case of
lipoatrophic diabetes with NASH leading to liver failure
13 In
lipoatrophic diabetes, a lack of fat is associated with
14 ikingly resembles that of humans with severe
lipoatrophic diabetes, including the lack of fat, marked
15 However, in contrast to other models of
lipoatrophic diabetes, there was no accumulation of fat
16 ribute to the insulin resistance observed in
lipoatrophic diabetes.
17 is, and fibrosis that can be associated with
lipoatrophic diabetes.
18 troglitazone may have therapeutic benefit in
lipoatrophic diabetes.
19 trol and increased body fat in patients with
lipoatrophic diabetes.
20 A-ZIP/F-1 mice, which have a severe form of
lipoatrophic diabetes.
21 -) double knockout mouse as a novel model of
lipoatrophic diabetes.
22 43 in the A-ZIP/F-1 mouse, a model of severe
lipoatrophic diabetes.
23 lin resistance and reduces hyperlipidemia in
lipoatrophic humans.
24 tin cotreatment normalizes insulin action in
lipoatrophic insulin-resistant animals.
25 ast, rosiglitazone remained effective in non-
lipoatrophic mice lacking liver PPAR gamma, suggesting t
26 metabolic phenotype of the A-ZIP/F-1 (AZIP)
lipoatrophic mouse is different depending on its genetic
27 -n sterol response element binding protein 1
lipoatrophic mouse.
28 le explanation for both the diabetic and the
lipoatrophic phenotype in Ncb5or(-/-) mice.